Key result
The Carpentier-Edwards Perimount Magna xenograft reduced patient-prosthesis mismatch (16.6% vs 40.7%) and mean pressure gradient (9.6 vs 13.6 mmHg, P<0.0001) compared to the standard Perimount valve.
Why the study?
Does the Carpentier-Edwards Perimount Magna xenograft improve hemodynamic performance compared to the standard Perimount valve in patients undergoing aortic valve replacement?
Cohort (n=80)
Does the Carpentier-Edwards Perimount Magna xenograft improve hemodynamic performance compared to the standard Perimount valve in patients undergoing aortic valve replacement?
Absolute Event Rate: 16.6% vs 40.7%
The Carpentier-Edwards Perimount Magna prosthesis significantly improves hemodynamic performance and reduces the incidence of patient-prosthesis mismatch compared to the standard Perimount valve.
No takes yet. Share an insight, caveat, or question.
May support Magna valve selection for lower PPM risk; hypothesis-generating and requires RCTs before changing AVR practice.
María José Dalmau (2006) conducted a cohort in Aortic valve replacement (n=80). Carpentier-Edwards Perimount Magna (CEPM) xenograft vs. Standard Perimount (CEPS) valve was evaluated on Patient-prosthesis mismatch (indexed EOA <=0.85 cm2/m2) in patients with valve sizes <=21 mm. The Carpentier-Edwards Perimount Magna xenograft reduced patient-prosthesis mismatch (16.6% vs 40.7%) and mean pressure gradient (9.6 vs 13.6 mmHg, P<0.0001) compared to the standard Perimount valve.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: